세계의 방사면역측정법 시장 : 시장 규모, 점유율, 동향 분석(제품별, 용도별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Radioimmunoassay Market Growth & Trends:

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

• The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
• The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
• The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
• North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
• 1.7. Details of primary research
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.1.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
    • 1.9.2.1. Approach 2: Volume price analysis
• 1.10. Research Scope and Assumptions
  • 1.10.1. List of Secondary Sources
  • 1.10.2. List of Primary Sources
  • 1.10.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
    • 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
    • 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
    • 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Presence of Ambiguous Regulatory Framework
    • 3.2.2.2. High Cost of RIA Equipment
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Supply Chain Analysis
  • 3.2.5. Distribution Channel
    • 3.2.5.1. Direct Sales
    • 3.2.5.2. Distributors Network
    • 3.2.5.3. E-commerce and Online Platforms
    • 3.2.5.4. Major Distributors
• 3.3. Radioimmunoassay Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Legal landscape
• 3.4. Reimbursement Overview
• 3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Analyzers
  • 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Reagents and Kits
  • 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Research
  • 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Clinical Diagnostics
  • 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Clinical Diagnostics Laboratories
  • 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical Industries
  • 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

• 7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.2.3. Competitive Insights
    • 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.3.3. Competitive Insights
    • 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.4.3. Competitive Insights
    • 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.2.3. Competitive Insights
    • 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.3.3. Competitive Insights
    • 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.4.3. Competitive Insights
    • 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.5.3. Competitive Insights
    • 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.6.3. Competitive Insights
    • 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Sweden
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.7.3. Competitive Insights
    • 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.8.3. Competitive Insights
    • 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.9.3. Competitive Insights
    • 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.5.3. Competitive Insights
    • 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.6.3. Competitive Insights
    • 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.7.3. Competitive Insights
    • 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Global Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
• 8.6. Company Profiles
  • 8.6.1. DIAsource
    • 8.6.1.1. Participant's Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Recent Developments
  • 8.6.2. Tecan Trading AG
    • 8.6.2.1. Participant's Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Recent Developments
  • 8.6.3. PerkinElmer
    • 8.6.3.1. Participant's Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Recent Developments
  • 8.6.4. DRG International Inc.
    • 8.6.4.1. Participant's Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Recent Developments
  • 8.6.5. Oxford BioSystems
    • 8.6.5.1. Participant's Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Recent Developments
  • 8.6.6. DiaSorin S.p.A.
    • 8.6.6.1. Participant's Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Recent Developments
  • 8.6.7. Eurodiagnostico, S.L.
    • 8.6.7.1. Participant's Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Recent Developments
  • 8.6.8. MP Biomedicals
    • 8.6.8.1. Participant's Overview
    • 8.6.8.2. Financial Performance
    • 8.6.8.3. Product Benchmarking
    • 8.6.8.4. Recent Developments
  • 8.6.9. Merck KGaA
    • 8.6.9.1. Participant's Overview
    • 8.6.9.2. Financial Performance
    • 8.6.9.3. Product Benchmarking
    • 8.6.9.4. Recent Developments